Tag:

R&D

Latest Headlines

Latest Headlines

Cubist makes Euro landfall with a $400M purse for antibiotics R&D

The antibiotics-focused Cubist Pharmaceuticals has opened up shop in Europe with a Swiss international headquarters, part of its plan to spend $400 million on infectious disease R&D this year and spotlight new treatments for global scourges.

Glaxo Ebola vax shows no adverse effects so far in first human trial

With the Ebola death toll mounting in West Africa, a Phase I trial of GlaxoSmithKline's experimental vaccine for the disease is underway at the U.S. National Institutes of Health.

Researchers deploy nanoparticles that can alter packaging of DNA

Researchers at the University of Maryland at Baltimore succeeded in delivering nanoparticles into cancer cells that changed packaged DNA into circular DNA, a breakthrough that may have applications for oncology and gene-based therapy. 

Vaxxas' nanopatch garners WHO support in search of polio vax application

Australian nanopatch developer Vaxxas signed on with the World Health Organization this week in an effort to co-opt the company's patch for use with the polio vaccine. The WHO will help fund the research and move it through preclinical and clinical studies as the organization seeks to make polio a thing of the past.

Novo Nordisk takes the plunge on obesity, eyeing Seattle for a huge R&D bet

In the midst of its first major foray into treating obesity, Novo Nordisk is liking what it sees in the space, and now the Danish giant plans to hire hundreds of researchers in a gambit to develop new treatments for the global scourge.

FDA greenlights first human study of Wearable Artificial Kidney

Months after clearing the Wearable Artificial Kidney for human clinical trials, the FDA gave medical researchers a green light to begin the first human study of the device in the United States.

Civitas, NeuroDerm, EyeGate to pursue IPO dreams, combined $165M on the line

Israel's NeuroDerm filed for a stock offering on the basis of its subcutaneous formulation for treating Parkinson's; Civitas, the developer of an inhaled formulation for the disease, is expected to debut on the Nasdaq Sept. 24; and EyeGate Pharmaceuticals, which employs low-voltage electrical current to deliver eye medication, also just filed for an IPO.

X-ray-triggered liposomes deliver precisely controlled cancer treatment

Combining chemotherapy and radiotherapy would be ideal for cancer treatment, but administering both at the same time can lead to unacceptable and often deadly levels of toxicity. Now researchers have developed liposomes that contain a chemotherapy drug activated by radiotherapy, offering both cancer-killing power and a targeted approach in a more controlled manner.

UPDATED: Bioresorbable stent developer Amaranth Medical initiates new clinical trial

Stent developer Amaranth Medical is launching the MEND-II clinical trial to test its Fortitude Sirolimus-Eluting Bioresorbable Scaffold, a sign that companies large and small are keenly the new treatment paradigm for coronary artery disease involving stents that disintegrate within the body after a couple of years.

Harvard researchers develop dialysis device to fight Ebola

Amid mounting industry pressure to unveil a therapy to counter the deadly Ebola outbreak, researchers are developing an innovative dialysis device that fights the disease by filtering blood.